• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Harrow (HROW) Could Be 44% Undervalued After Accounting Leadership Change

    Simply Wall St·09/06/2026 05:16:58
    Listen to the news

    Executive change at Harrow sets new focus on accounting leadership

    Harrow (HROW) disclosed that Chief Accounting Officer and principal accounting officer Randall E. Pollard left his roles on 4 September 2026, with President and CFO Andrew R. Boll now also serving as principal accounting officer.

    The board assigned Boll the additional responsibilities without extra compensation. The change concentrates financial oversight within Harrow’s senior leadership and may prompt investors to reassess how the company manages reporting and controls.

    Harrow’s share price closed at US$38.54 on 4 September, with short term momentum mixed as the 7 day share price return of 3.41% contrasts with a weaker 30 day share price return that is down 4.70%.

    Over a longer horizon, investors have seen a 4.19% total shareholder return over the past year and a 3 year total shareholder return of 159.70%. This helps put this executive reshuffle into the context of a stock that has already delivered significant gains for long term holders.

    Spot similar momentum and leadership stories by scanning our curated 19 high quality undiscovered gems alongside Harrow.

    Harrow trades at a steep discount to both analyst targets and one intrinsic value estimate after this executive reshuffle. Is the market rightly cautious about the risks, or overstating concerns around this growing eyecare platform?

    Most Popular Narrative: 43.6% Undervalued

    Harrow's most followed valuation narrative places fair value at $68.38, well above the last close at $38.54, which frames this accounting leadership change against a stock already seen as discounted.

    The rapidly growing demand for Harrow's portfolio of specialty ophthalmic drugs, particularly VEVYE, IHEEZO, and TRIESENCE, is positioned to accelerate further as aging populations and increased prevalence of chronic ocular diseases expand the baseline patient pool, supporting sustainable long-term revenue growth.

    Read the complete narrative. Read the complete narrative.

    Want to see what sits behind that fair value gap? The narrative leans on brisk revenue expansion, sharply higher margins, and a future earnings profile that supports a richer multiple. The full breakdown shows how those ingredients combine into that $68.38 figure.

    Result: Fair Value of $68.38 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, this Harrow narrative can be tested quickly if pricing pressure on key drugs or slower uptake for products like VEVYE and IHEEZO reduces revenue.

    Find out about the key risks to this Harrow narrative.

    Next Steps

    The narrative around Harrow may sound upbeat, yet the real test is how the numbers stack up for you. Review the company's 3 key rewards.

    Looking for more investment ideas beyond Harrow?

    If Harrow has your attention, do not stop here. Fresh ideas across the market can help you stress test your thinking and sharpen your next move.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.